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Abstract 
 
This work describes a liquid chromatography-electrospray tandem mass spectrometry (LC-
ESI-MS/MS) method for detection of desmopressin in human plasma in the low femtomolar 
range. 
Desmopressin is a synthetic analogue of the antidiuretic hormone arginine vasopressin and it 
might be used by athletes as masking agent in the frame of blood passport controls. Therefore, 
it was recently added by the World Anti-Doping Agency (WADA) to the list of prohibited 
substances in sport as a masking agent. 
Mass spectrometry characterization of desmopressin was performed with a high-resolution 
Orbitrap-based mass spectrometer. Detection of the peptide in the biological matrix was 
achieved using a triple quadrupole instrument with an electrospray ionization (ESI) interface 
after protein precipitation, weak cation solid phase extraction and HPLC separation with an 
octadecyl reverse phase column. Identification of desmopressin was performed using three 
product ions, m/z 328.0, m/z 120.0, and m/z 214.0, from the parent ion, m/z 535.5. 
The extraction efficiency of the method at the limit of detection was estimated at 40% (n=10), 
the ion suppression at 5% (n=10), and the limit of detection was 50 pg/ml (S/N> 3). 
Selectivity of the method was verified against several endogenous and synthetic desmopressin 
related peptides. The performance and the applicability of the method were tested by analysis 
of clinical samples after administration of desmopressin via intravenous, oral, and intranasal 
routes. Only after intravenous administration, desmopressin could be successfully detected.
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Introduction 
Desmopressin, 1-desamino-8-D-arginine-vasopressin (dDAVP), is a synthetic analogue of 
arginine [Arg8]-vasopressin (AVP), a cyclic peptide hormone with antidiuretic properties, 
synthesized in the hypothalamic cells and released from neurohypophysis. Desmopressin 
(monoisotopic mass: 1068.4269 Da) is obtained by deamination at the N-terminal 1 position 
of Avp and replacement of 8-L-arginine with its D-isomer (Figure 1) [1-3]. 
Compared with AVP, desmopressin has a longer lasting and more potent antidiuretic effect 
and is devoid of vasopressor effects [2, 4, 5]. Desmopressin is therapeutically used for the 
treatment of diabetes insipidus [4; 5], primary nocturnal enuresis (bed wetting) [6-9] type I 
von Willebrand disease, and hemophilia A [11-14]. 
Desmopressin can induce hemodilution decreasing hematocrit levels and hemoglobin 
concentrations. These values are important hematological parameters used to detect blood 
doping in sports [15-16]. 
Therefore, desmopressin has recently been added by the World Anti-Doping Agency 
(WADA) to the 2011 Prohibited List as a masking agent [17]. 
Previous methods for the detection of desmopressin in biological fluids were performed only 
for clinical purposes, by immunoassays. These methods provided sensitive and cost effective 
analyses [8, 18-22], but with some important limitations, in particular concerning specificity 
[23]. 
Liquid chromatography-mass spectrometry (LC-MS) shows good sensitivity together with a 
high degree of selectivity and specificity to allow for unequivocal confirmation of the 
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presence of a substance based on its molecular weight. Hence LC-MS methods have become 
the method of choice for the analysis of peptide [24]. 
Until now, only one study using LC-MS to identify desmopressin has been published [25]. 
This method was applied for the analysis of skin samples and has a limit of detection (LOD) 
of 10 ng/ml (≈ 10 picomoles). Obviously, this matrix is not applicable in the field of sport 
drug testing. Hence, the present work had the aim to develop and validate a LC-ESI-MS/MS 
method for detection of desmopressin in plasma fit for anti-doping purposes.  
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Materials and methods 
 
Chemicals and reagents 
All the chemicals and solvents used for sample pretreatment and chromatography were 
analytical grade or HPLC grade. Desmopressin was a kind gift from Ferring Pharmaceuticals 
(Malmö, Sweden). AVP and [deamino-Cys1, Val4, D-Arg8]-vasopressin were purchased from 
Sigma Aldrich (Saint Louis, USA). Oxytocin, [Lys8]-vasopressin, and terlipressin were 
purchased from Selleck Chemicals LLC (Houston, USA). Desmopressin and analogues were 
all available as acetate salts. Stock and working solution were all prepared using 2% acetic 
acid (HOAc) aqueous solutions. Acetonitrile (ACN) and water (H2O) were purchased from 
BioSolve (Lexington, USA); methanol (MeOH) was purchased from Fisher Scientific (Aalst, 
Belgium); 25% ammonia (NH4OH) aqueous solution and glacial HOAc were purchased from 
Merck (Darmstadt, Germany); trifluoroacetic acid (TFA) was purchased from Sigma-Aldrich. 
Saturated ammonium sulfate ((NH4)2SO4) solution was prepared by dissolving 800 g of 
(NH4)2SO4 (Merck, Darmstadt, Germany) in 1000 ml of H2O at room temperature. The 
resulting solution was gently poured into a second glass bottle in order to get rid of the 
undissolved crystals of (NH4)2SO4, then 20 ml of 25% NH4OH were added to 1 l of the 
(NH4)2SO4 solution. 
Only low binding microcentrifugal vials, type Eppendorf (Eppendorf, Hamburg, Germany) 
and low retention pipette tips (Sorenson Biosciences, Salt Lake City, USA) were used to 
prepare stock solutions (100 µg/ml) and working solutions (10 ng/ml). AVP was always 
added to desmopressin working solutions at a concentration of 2.5 ng/mL, in order to prevent 
desmopressin adsorption to solid surfaces. 
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Plasma samples 
Method development and validation were performed using left-over plasma samples obtained 
from Red Cross Blood Transfusion Center (Gent, Belgium, approval number 20100609). 
Desmopressin containing plasma samples were obtained from the Department of Internal 
Medicine (Endocrinology and Hematology) of the Ghent University hospital, with the 
approval of the Ethical Committee of the Ghent University (reference: B67020108809). 
Sample preparation 
2 ml of plasma were spiked with 50 µl of [deamino-Cys1, Val4, D-Arg8]-vasopressin (50 
ng/ml) as internal standard. Then, 2 ml of saturated (NH4)2SO4 solution, containing 2% 
NH4OH, were added and the samples were centrifuged (4100 g, 1 h, 2°C) to precipitate 
plasma proteins. A further purification of the supernatant was performed by solid phase 
extraction with Oasis® WCX (60 mg) cartridges, purchased from Waters (Milford, USA). The 
column was first activated with 2 ml of MeOH and subsequently rinsed with 2 ml of H2O. 
After the sample was loaded, the column was washed first with 2 ml of 5% NH4OH aqueous 
solution, then with 2 ml of 60:40 H2O:MeOH mixture. Finally, samples were eluted with 1.25 
ml of a solution consisting of 80:20 MeOH:(5% HOAc in H2O). The eluate was subsequently 
evaporated to dryness with a centrifugal evaporator (45°C, 240 g, 6-8 h), and then dissolved 
in 40 µl of 95:5 H2O:ACN, 0.1% HOAc, 0.01% TFA prior to LC-MS analysis. 
Liquid chromatography  
HPLC separation was achieved with a Surveyor MS Pump Plus coupled with a Surveyor Plus 
autosampler (Thermo Scientific, Bremen, Germany) using a Zorbax 300SB-C18 reverse-
phase column (1.0 x 50 mm, 3.5 µm) protected with a Zorbax 300SB-C8 guard column, both 
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from Agilent Technologies (Santa Clara, USA). The use of the C8 guard column was adopted 
from a previous work from Thevis [26]. 
For each sample, 30 µl were injected. A binary gradient was used: mobile phase A consisted 
of H2O, 0.1% HOAc, 0.01% TFA; mobile phase B consisted of ACN, 0.1% HOAc, 0.01% 
TFA. Gradient elution was as follows: 95% A for 1.5 minutes, then decreased linearly to 0% 
A in 8.5 minutes, and held at 0% A for 5 minutes, followed by an increase to 95% A in 0.1 
minutes. Then the system was equilibrated for 10 minutes before next injection (total run 
time: 25 minutes). A constant flow rate of 50 µl/min was maintained. 
Mass spectrometry 
MS/MS method development for detection of desmopressin in human plasma was performed 
on a TSQ Quantum Discovery Triple Stage Quadrupole Mass Spectrometer (Thermo 
Scientific, Bremen, Germany) equipped with an ESI source operating in positive mode The 
ESI–MS operating variables used in this study were as follows: capillary voltage, 3.5 kV; 
source temperature, 350 °C; sheat gas pressure, 30 psi; auxiliary gas pressure, 10 psi; tube 
lens offset, 84V. 
Mass spectrometry characterization of desmopressin and related peptides was performed on 
an Exactive benchtop Orbitrap-based mass spectrometer (Thermo Scientific, Bremen, 
Germany) operating in positive HCD scan at 50 eV. The sheath gas was set to 60 (arbitrary 
units), the aux gas set to 30 (arbitrary units) and the capillary temperature set to 350°C. The 
capillary voltage and spray voltage were set to 30 V and 3 kV, respectively. The instrument 
was operated in full scan mode from m/z 60–1200 at 100,000 resolving power. The data 
acquisition rate was 1 Hz. 
Disulfide bridge reduction 
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In order to get additional information on the MS behavior of desmopressin, reduction of the 
disulfide bridge (Mpa1-Cys6) was performed by adding 200 µl of dithiothreitol in 0.2 mM 
ammonium acetate buffer at pH=5.5 (both from Sigma-Aldrich) to readily prepared solutions 
of the peptide and incubating the resulting solution for 30 minutes at 56 °C. 
 
Validation 
In accordance with Eurachem validation guidelines [27], 10 human plasma samples, were 
spiked at different levels (5, 10, 25, 50, 100 pg/ml) to determine the LOD. 
The detection limit was defined as the lowest level at which a compound could be identified 
in all 10 plasma samples with  the diagnostic ions present with a signal-to-noise (S/N) ratio 
greater than 3 and a retention time difference of less than 0.2 min to the reference. 
Selectivity was tested by analysing plasma samples spiked with desmopressin and its 
analogues at a concentration of 100 pg/ml.  
The analogues included the endogenous hormones AVP and oxytocin, and the synthetic 
derivatives [deamino-Cys1, Val4, D-Arg8]-vasopressin, [Lys8]-vasopressin, and terlipressin. 
Specificity was tested during the validation procedure in order to check the absence of 
endogenous interferences. The 10 blank plasma samples used for determining analytical 
performances of the method were extracted and analyzed as described above. 
Extraction efficiency and matrix effect  
To evaluate the extraction efficiency, the 10 negative plasma samples, used for the validation, 
were spiked with desmopressin at 50 pg/ml and processed together with non-spiked plasma 
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samples. The extracts of the non-spiked plasma samples were spiked after evaporation and 
before HPLC injection. After analysis the obtained peak areas for the product ion at m/z 328.0 
of the two sets of samples were compared.  
Matrix effect was evaluated by comparing the peak areas (m/z 328.0) of the plasma samples 
spiked after extraction with a reference solution of desmopressin at 50 pg/ml, corresponding 
to a 100% recovery (0% matrix effect). 
Excretion studies 
7 plasma samples from patients who received desmopressin were used in the study. Four 
patients received desmopressin via intranasal (≈ 10 µg/dose), two orally (200 µg) and one 
intravenously (20 µg). Blood samples were immediately centrifuged and plasma was 
separated. When not directly analyzed, plasma samples were stored at <-20°C awaiting 
analysis.
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Results and discussion 
 
Mass spectrometry 
Direct infusion of desmopressin and analogues was performed in order to determine the best 
mass spectrometry conditions for the design of the MRM method. A full scan MS analysis 
was first performed in order to identify the most abundant precursor ions and subsequently the 
collision energy was optimized for the most diagnostic fragments. 
Desmopressin showed excellent ionization, due to the presence of an arginine residue (Arg8), 
containing the guanidinium group with a high proton affinity. The double charged ion 
[M+2H]+2 was observed as base peak for desmopressin (Figure 2) but also for the analogues. 
The single charged ion [M+H]+ only achieved a relative abundance of 20%. The collision-
induced dissociation of desmopressin base peak (m/z 535.5) led to the formation of several 
fragments. Fragment ions at m/z 328.0, m/z 120.0 and m/z 214.0 were selected as diagnostic. 
Several other product ions, also present in the spectrum, were also recorded during mass 
spectrometry characterisation, but they were not specific or not sensitive enough using a 
criteria of S/N >3 to be considered for reliable detection. The other vasopressin-related 
peptides presented similar ESI spectra. Also, the ion [M+2H]+2 appeared as base peak in the 
full scan MS spectra of each peptide. Additionally, the peptides presented several common 
fragments, but different precursor ions and retention times were observed, therefore method 
selectivity was guaranteed. Results from infusion experiments for MS/MS optimization of the 
investigated compounds are summarized on Table 1. 
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The three diagnostic ions selected for MRM method were further investigated by high-
resolution mass spectrometry. Figure 3 shows the fragmentation patterns of the native (a) and 
the reduced (b) peptide generated by HCD at 50 eV at high resolution. All the relevant 
fragments are single-charged and some of them present a neutral loss of NH3. Moreover, it is 
possible to notice that in the native molecule all the significant high-mass fragments (y2-NH3, 
y3-NH3, y3, b6) contain the Arg8. The b6-NH3 fragment, which presents an intramolecular 
disulfide bridge between C1 and C6 and is adjacent to a proline residue, represents the only 
exception [28]. Reduction of the disulfide bridge provided additional information on the MS 
characterization of desmopressin, yielding to the identification of the complete y3-y7 sequence. 
The contemporary presence in fragment ion y3 of Arg8 and Pro6 at the N-terminal, which 
usually causes enhanced fragmentation attributed to the greater basicity of prolin substituted 
nitrogen group [29], can explain the elevated abundance of this fragment in the MRM mode. 
Liquid chromatography 
Chromatographic separation was achieved with a C18 column, which allowed satisfactory 
peak shapes and chromatographic retention for desmopressin, the internal standard and the 
carrier peptide. A high percentage (90%) of ACN was required to elute desmopressin, which 
presented an average retention time (tR) of 10.07 and the IS (tR=10.75 min). The carrier 
peptide Avp that contains the terminal amino moiety eluted earlier (tR=3.63 min). 
Additionally, other desmopressin related peptide, including the endogenous hormone oxytocin 
and the synthetic analogues [Lys8]-vasopressin, and terlipressin were analyzed to further 
investigate method selectivity. Results, also summarized in Table 1, demonstrated that the 
chromatography is sufficient to separate desmopressin from these peptides. In fact, oxytocin 
elute at 9.88 min, [Lys8]-vasopressin at 3.50 min, and terlipressin at 3.76 min. 
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Sample preparation 
Since no LC-MS based method for detection of desmopressin in plasma has been described 
previously, the sample preparation procedures available from the literature were all related to 
the function of immunoassays. These approaches are based mainly on previous work of 
Lundin et al [21, 22]. Desmopressin is a small, highly basic peptide, resulting in good 
solubility, without a significant tertiary structure that can undergo denaturation during protein 
precipitation. Therefore Lundin et al. [21] successfully used protein precipitation with ice-
cold acetone as sample clean-up. To optimize this protein precipitation step, the application of 
acetone, methanol, saturated (NH4)2SO4 and ethanol [30] were evaluated during method 
development. Deproteination of the samples using saturated (NH4)2SO4, gave the best results 
regarding S/N response. Additionally, omitting the use of an organic solvent to precipitate 
bulk proteins avoids the requirement to evaporate the deproteinated sample before application 
to the SPE in the next step. Finally, the use of the protein precipitation allowed a 5-fold 
increase of the MS response compared with samples that were processed only with SPE. To 
further decrease sample preparation time, 15 and 30 min centrifugation instead of 60 min was 
considered. However, due to the lower centrifugation time, deproteination was less complete. 
Using centrifugation devices with higher speed can further shorten centrifugation times. 
SPE was considered to further concentrate and desalt the samples. In particular, cation 
exchange columns were investigated, because desmopressin is a basic peptide with a pKa 
value of approximately 12. Mixed-mode ion-exchange (MCX) columns were initially 
investigated. However, desmopressin could not be recovered from this type of column during 
the elution step since this type of column is only applicable for weak basic compound. 
Weak-cation ion exchange  WCX)- columns proved to be particularly suitable for the clean up 
of strong basic compounds  allowing, compared to octadecyl (C18) and hydrophilic-lipophilic 
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balance (HLB) sorbents, to eliminate efficiently acid and slightly basic matrix components. 
These resulted in a higher grade of purification.  
Since the WCX protocol requires a basic pH to load the samples on the SPE column, the 
(NH4)2SO4 saturated solution was basified with NH4OH (pH 9.2). No differences in 
desmopressin responses were registered for protein-precipitation compared with the non-
basified (NH4)2SO4 saturated solution. The presence of 20% water in the elution solvent, 
resulting in a longer evaporation time, guaranteed the best results in terms of sensitivity.  
Choice of internal standard and carrier peptide 
[deamino-Cys1, Val4, D-Arg8]-vasopressin was chosen as internal standard since it presents a 
very similar chemical structure, pKa, and retention times (∆tR≈ 0.7 min) to desmopressin, and 
therefore a similar behavior during the entire analytical process. Since the degree of 
adsorption of a peptide or protein is not always predictable, several precautions were adopted 
to prevent this phenomenon, including the use of low binding plastic and the use of a carrier 
peptide. AVP was considered as a suitable carrier peptide for working solutions since it 
presents a very different retention time (∆tR≈ 6.4 min) from the target analyte, which means 
no interferences with its detection, and, additionally, a low cost for the standard reference. We 
registered only a slight decreasment (approximately 10´%) in MS response when diluted 
working solutions of 10 ng/ml of desmopressin, not containing AVP as carrier peptide, were 
analyzed, whereas no significant differences were recorded when AVP was added to plasma 
sample (500 ng/ml) at the beginning of the sample preparation. Hence, desmopressin 
adsorption did not occur or was negligible during sample preparation. 
Additionally, stability of desmopressin working solution stored at 4°C was tested by 
preparing a new solution (10 pg/ml) every month and comparing it with the previous by LC-
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MS analysis. After 4 months, no significant difference was noticed in peak areas of the 
various solutions. Moreover, desmopressin working solution was demonstrated to be stable 
after incubation at 56°C for 6 hours. 
Method validation 
The method showed an LOD of 50 pg/ml, with a signal to noise ratio (S/N) greater than 3 for 
the three transitions in all plasma samples that were analyzed. Maximum tolerance windows 
(% of base peak m/z 328.0) were set at ±10% (absolute) for m/z 120.0 and ±5% (absolute) for 
m/z 214.0, according to the WADA identification criteria for LC-MS qualitative assays [31] 
that recommend the use of minimum two transitions for MRM-based methods. Nevertheless, 
using only one transition is also allowed.. According to the abundance recorded using the 
product ion at m/z 328.0, the average extraction efficiency (n=10) of the preparation was 
estimated at 40% (±4%). Signal reduction due to ion suppression in the ESI source (n=10) 
was limited to 5% (±14%). 
The method also exhibited good selectivity since the related peptides presented different 
retention time, as shown in Table 1. Mass overlapping for mass spectrometry detection was 
avoided, thereby ensuring analytical selectivity. AVP, [Lys8]-vasopressin, and terlipressin, 
whose N-terminal is not deaminated, elute earlier (3.5-3.80), whereas desmopressin, 
[deamino-Cys1, Val4, D-Arg8]-vasopressin (both deaminated) and oxytocin (which presents 
the hydrophobic amino acid isoleucine) require a higher percentage of organic solvent. 
The method can be used for the analysis of an elevated number of samples per batch and the 
whole analysis can be performed in a single day, since the only time consuming step 
(evaporation of the SPE eluate) requires only few hours. 
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Method application 
The suitability of our method was evaluated by the analysis of 7 plasma samples from patients 
who received desmopressin. Four patients received desmopressin intranasally, two orally and 
one intravenously. Administered dose and collection times are summarized in Table 2. 
Detection of desmopressin after oral administration could not be achieved, even taking into 
account only the most abundant transition (m/z 535 -> 328, LOD= 10 pg/ml). Indeed, orally 
administered desmopressin has a very low bioavailability. Osterberg et al [19] reported 
maximum plasma levels < 50 pg/ml (t= 90 min) after oral administration of a therapeutic dose 
of 240 µg.Similarly, desmopressin was not detectable after nasal administration. The lower 
dose (≈ 10 µg) and the generally lower bioavailability of this type of formulation could 
explain the non-detection. After intravenous administration of a 20 µg dose, desmopressin 
could be detected in an unambiguous way (Figure 4b). 
It can be concluded that desmopressin detection in plasma, related to anti-doping analysis is 
not realistic after oral or intranasal administration. In particular since oral administration has 
shown to effect hematocrit levels [12]. Intravenous application seems unlikely due to its 
invasive nature. Hence, it will be necessary to consider other detection strategies to increase 
the possibility to detect the misuse of this peptide.by LC-MS.  According to Agerso et al. 
[20], an important fraction of desmopressin is eliminated from the body via renal clearance. 
Hence urinary detection of desmopressin will be further investigated.
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Conclusions 
 
For the first time a sensitive LC-ESI-MS/MS method for the detection of desmopressin in 
human plasma for doping purposes was described. Validation of the method showed an LOD 
of 50 pg/ml when three transitions were considered, and 10 pg/ml when only the most 
abundant transition (m/z 328) was monitored. The method exhibited also good selectivity and 
specificity. Application of the method to administration samples showed that desmopressin 
was detectable when administered intravenously, but not after oral and intranasal 
administration. The results of the analysis of the administration samples are in agreement with 
the literature describing low bioavailability and short plasmatic half-lives after oral and 
intranasal application, hampering its detection. 
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Figure captions 
Figure 1 
Compared to arginine vasopressin, desmopressin's Cys1 has been deaminated, and the Arg8 is 
in the dextro rather than the levo form. 
Figure 2 
High-resolution full scan MS spectra of desmopressin (a), and isotopic pattern of its base peak 
[M + 2H](2+) (b).  
Figure 3 
HCD spectra of desmopressin acquired at 50eV (a). The fragmentation scheme shows that all 
the most abundant high MW fragments contain the arginine residue, except b6, that is 
stabilized by the disulfide bridge. Reduction of the disulfide bridge (b) yield to the 
identification of the sequence y3-y7. 
Figure 4 
Extracted ion chromatograms for the product ions m/z 328.0, m/z 120.0, m/z 214.0 (precursor 
ion m/z 535.5) respectively in a blank plasma (a), after fortification with desmopressin at 
LOD concentration (50 pg/ml) (b), before (c) and after administration of intravenous 
desmopressin (d). Samples were all prepared and analyzed according to the described assay. 
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Table captions 
Table 1 
Amino acid sequence, retention times and MRM conditions for ESI-MS/MS analysis of 
desmopressin and related peptides. Desmopressin and its analogues present several common 
product ions, but different the retention time and parent ion. The double charged ion resulted 
to be the most abundant for all the investigated peptides. 
Table 2 
Summary of blood specimens from excretion study, collected after administration of 
desmopressin via different routes. 
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